Objective: To investigate the cytological findings of lobular endocervical glandular hyperplasia (LEGH) associated with adenocarcinoma and to clarify its characteristics and the coexisting adenocarcinoma using histochemistry and immunohistochemistry. Methods: Eighteen surgical cases of LEGH of the uterine cervix were retrospectively reviewed and classified into 3 groups: pure (pure type), atypical (atypical type), and LEGH with adenocarcinoma (mixed type). The mixed type is defined as LEGH or atypical LEGH with in situ or invasive adenocarcinoma. Cytological findings of conventional endocervical smear specimens (Papanicolaou stain) were analyzed. Histochemistry (periodic acid-Schiff reaction) and immunohistochemistry (M-GGMC-1, Muc-6 glycoprotein, and Ki-67) were performed using tissue specimens. Results: Cytologically, the pure type (7 cases) is characterized by glandular cell clusters that tended to form monolayered sheets with uniformly small nuclei and contain golden-yellowish mucin, whereas atypical (5 cases) and mixed (6 cases) types are characterized by glandular cell clusters similar to those of the pure type, but with complex glandular structures and mucin localization on the surface of glandular cell clusters. Ki-67 labeling index was significantly higher in atypical and mixed types than that in the pure type. Gastric-type mucinous carcinoma (MC-G) was observed in 2 out of 6 cases with mixed type. Conclusions: LEGH is found to be associated with adenocarcinoma types other than MC-G. Complex glandular structures or mucin localization on the surface of glandular cell clusters may be useful cytological findings to detect atypical and mixed types of LEGH.

1.
Nucci
MR
,
Clement
PB
,
Young
RH
.
Lobular endocervical glandular hyperplasia, not otherwise specified: a clinicopathologic analysis of thirteen cases of a distinctive pseudoneoplastic lesion and comparison with fourteen cases of adenoma malignum
.
Am J Surg Pathol
.
1999 Aug
;
23
(
8
):
886
91
.
2.
Wilbur
DC
,
Mikami
Y
,
Colgan
TJ
,
Park
KJ
,
Ferenczy
AS
,
Ronnett
BM
, et al
Chapter 7 Benign glandular tumours and tumour-like lesions
. In:
Kurman
RJ
,
Carcangiu
ML
,
Herrington
S
,
Young
RH
, editors.
WHO classification of tumours of female reproductive organs
.
Lyon
:
IARC Press
;
2014
. p.
183
94
.
3.
Mikami
Y
,
Kiyokawa
T
,
Hata
S
,
Fujiwara
K
,
Moriya
T
,
Sasano
H
, et al
Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’
.
Mod Pathol
.
2004 Aug
;
17
(
8
):
962
72
.
4.
Hayashi
I
,
Tsuda
H
,
Shimoda
T
,
Maeshima
A
,
Kasamatsu
T
,
Yamada
T
, et al
Difference in cytoplasmic localization pattern of neutral mucin among lobular endocervical glandular hyperplasia, adenoma malignum, and common adenocarcinoma of the uterine cervix
.
Virchows Arch
.
2003 Dec
;
443
(
6
):
752
60
.
5.
Okuyama
R
,
Hashimoto
H
,
Miura
T
,
Sugita
M
,
Arai
M
,
Tsunoda
H
, et al
Two cases of adenocarcinoma in situ arising in lobular endocervical glandular hyperplasia indicating localization of mucin on the cluster surface as an early cytological finding of malignant transformation
.
Diagn Cytopathol
.
2017 Sep
;
45
(
9
):
842
7
.
6.
Talia
KL
,
McCluggage
WG
.
The developing spectrum of gastric-type cervical glandular lesions
.
Pathology
.
2018 Feb
;
50
(
2
):
122
33
.
7.
Nara
M
,
Hashi
A
,
Murata
S
,
Kondo
T
,
Yuminamochi
T
,
Nakazawa
K
, et al
Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection
.
Gynecol Oncol
.
2007 Aug
;
106
(
2
):
289
98
.
8.
Sasajima
Y
,
Mikami
Y
,
Kaku
T
,
Kiyokawa
T
,
Ohishi
Y
,
Hamada
T
, et al
Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix
.
Histopathology
.
2008 Oct
;
53
(
4
):
487
90
.
9.
Takatsu
A
,
Shiozawa
T
,
Miyamoto
T
,
Kurosawa
K
,
Kashima
H
,
Yamada
T
, et al
Preoperative differential diagnosis of minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia of the uterine cervix: a multicenter study of clinicopathology and magnetic resonance imaging findings
.
Int J Gynecol Cancer
.
2011 Oct
;
21
(
7
):
1287
96
.
10.
Mikami
Y
,
Hata
S
,
Melamed
J
,
Fujiwara
K
,
Manabe
T
.
Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype
.
Histopathology
.
2001 Oct
;
39
(
4
):
364
72
.
11.
Mikami
Y
,
Kojima
A
,
Kiyokawa
T
,
Manabe
T
.
Ki67 labelling index and p53 status indicate neoplastic nature of atypical lobular endocervical glandular hyperplasia (ALEGH)
.
Histopathology
.
2009 Sep
;
55
(
3
):
362
4
.
12.
Hashi
A
,
Yuminamochi
T
,
Xu
JY
,
Kondo
T
,
Katoh
R
,
Hoshi
K
, et al
Intranuclear cytoplasmic inclusion is a significant diagnostic feature for the differentiation of lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma of the cervix
.
Diagn Cytopathol
.
2008 Aug
;
36
(
8
):
535
44
.
13.
Hata
S
,
Mikami
Y
,
Manabe
T
.
Diagnostic significance of endocervical glandular cells with “golden-yellow” mucin on pap smear
.
Diagn Cytopathol
.
2002 Aug
;
27
(
2
):
80
4
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.